Insmed (LTS:0JAV) Total Stockholders Equity: $757 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0JAV Insmed Inc LTS:0JAV
59 GF Score
Price $118.54
GF Value $207.72
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Insmed Total Stockholders Equity?

Insmed LTS:0JAV 59 Total Stockholders Equity is $757 Mil as of Jun. 2026. GuruFocus rates LTS:0JAV with a GF Score™ of 59/100 and a GF Value™ of $207.72 (Possible Value Trap). The stock has 4 warning signs investors should review.

Insmed's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $757 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Insmed's Book Value per Share for the quarter that ended in Jun. 2026 was $3.47. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Insmed's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.77.

Insmed  (LTS:0JAV) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Insmed's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(757.494-0)/218.281
=3.47

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Insmed's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(9.815 + 570.066) / 757.494
=0.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insmed Total Stockholders Equity Related Terms

Insmed Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Insmed's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insmed Total Stockholders Equity Chart

Insmed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 410.47 87.95 -331.92 285.38 738.98

Insmed Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,249.74 945.57 738.98 704.85 757.49
LTS:0JAV
59GF Score
Insmed Inc LTS:0JAV
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $757 Mil mean?
Insmed (LTS:0JAV) has a Total Stockholders Equity of $757 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Insmed and its competitors.
Is Insmed's Total Stockholders Equity too high?
Insmed's current Total Stockholders Equity is $757 Mil. Overall, Insmed has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Insmed's Total Stockholders Equity compare to BNTX and INCY?
Insmed's Total Stockholders Equity of $757 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Insmed and its competitors. Insmed's current Total Stockholders Equity is $757 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insmed stock overvalued right now?
Based on GuruFocus' analysis, Insmed (LTS:0JAV) is currently considered Possible Value Trap. The stock's GF Value™ is $207.72, compared to a current price of $118.54 — trading 42.9% below its estimated fair value. The current Total Stockholders Equity is $757 Mil. Insmed's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Insmed (LTS:0JAV), the current Total Stockholders Equity is $757 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insmed (LTS:0JAV) Overvalued in 2026?

Based on GuruFocus' analysis, Insmed stock appears to be undervalued. The current stock price of $118.54 is trading 42.9% below its estimated GF Value™ of $207.72. GuruFocus considers Insmed to be Possible Value Trap.

Key valuation signals for LTS:0JAV:

  • Total Stockholders Equity: $757 Mil
  • GF Value™: $207.72 vs. price of $118.54 (42.9% below fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the LTS:0JAV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insmed Business Description

Address 700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
59GF Score

Get the complete analysis for LTS:0JAV

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$118.54
Price
$207.72
GF Value